<![CDATA[Riz-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC]]>

Data ReadoutpositiveRiz-RezPositive

AI Analysis

Summary

Riz-Rez demonstrated anti-tumor activity in extensive-stage small cell lung cancer in the phase 1a/b EMBOLD PanTumour-101 study. Investigators will present detailed findings at the ESMO Congress 2026.

Clinical Trial Data

Phase

Phase_1

Outcome Details

Riz-Rez produced anti-tumor activity in extensive-stage SCLC in the phase 1a/b EMBOLD PanTumour-101 study; detailed findings to be presented at ESMO Congress 2026.

Importance:5/10

Sentiment:

0.40

SCLConcologyPhase 1ESMO 2026anti-tumor activityEMBOLD PanTumour-101

Related Companies

$DFPH $MDCE

Read the original article

Published by Cancer Network on October 19, 2026 4:00 PM

Read Original